Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Sep;93(3):313–317. doi: 10.1111/j.1365-2249.1993.tb08178.x

Suppression of autoimmune disease in NZB/W F1 mice by treatment with the novel immunomodulator BTS 63155.

P Appleby 1, G Telford 1, G B Naylor 1
PMCID: PMC1554905  PMID: 8370159

Abstract

Autoimmune disease in NZB/W F1 mice was treated from 23 weeks of age with the novel immunomodulator BTS 63155 and, for comparative purposes, the established immunosuppressive agent cyclosporin A. Both drugs significantly improved survival compared with untreated controls. Lupus nephritis was also significantly reduced in the drug-treated groups, and this was related to reduced glomerular deposition of IgG. Autoantibody (ANA) levels were lowered by treatment with cyclosporin A, but not by BTS 63155. This latter finding may indicate a different mode of action for the two drugs. In a long term study, neither drug effected a complete cure, as autoimmune disease recurred on withdrawal of drug treatment.

Full text

PDF
313

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bundick R. V., Eady R. P. The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice. Clin Exp Immunol. 1992 Aug;89(2):179–184. doi: 10.1111/j.1365-2249.1992.tb06929.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cavallo T., Graves K., Granholm N. A. Murine lupus nephritis. Effects of glucocorticoid on circulating and tissue-bound immunoreactants. Lab Invest. 1983 Oct;49(4):476–481. [PubMed] [Google Scholar]
  3. Gunn H. C., Ryffel B. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis. Clin Exp Immunol. 1986 May;64(2):234–242. [PMC free article] [PubMed] [Google Scholar]
  4. Gunn H. C. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies. Clin Exp Immunol. 1986 May;64(2):225–233. [PMC free article] [PubMed] [Google Scholar]
  5. Hahn B. H., Knotts L., Ng M., Hamilton T. R. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice. Arthritis Rheum. 1975 Mar-Apr;18(2):145–152. doi: 10.1002/art.1780180212. [DOI] [PubMed] [Google Scholar]
  6. Holgate C. S., Jackson P., Cowen P. N., Bird C. C. Immunogold-silver staining: new method of immunostaining with enhanced sensitivity. J Histochem Cytochem. 1983 Jul;31(7):938–944. doi: 10.1177/31.7.6189883. [DOI] [PubMed] [Google Scholar]
  7. Israel-Biet D., Noel L. H., Bach M. A., Dardenne M., Bach J. F. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice. Clin Exp Immunol. 1983 Nov;54(2):359–365. [PMC free article] [PubMed] [Google Scholar]
  8. Izui S., Elder J. H., McConahey P. J., Dixon F. J. Identification of retroviral gp70 and anti-gp70 antibodies involved in circulating immune complexes in NZB X NZW mice. J Exp Med. 1981 May 1;153(5):1151–1160. doi: 10.1084/jem.153.5.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones M. G., Harris G. Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol. 1985 Jan;59(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  10. Nishikawa M., Nagata M., Takeda M., Sato T., Sanaka T., Sugino N. The effects of ciclosporin on the renal histopathological aspects in (NZB x NZW)F1 mice. Jpn J Exp Med. 1989 Aug;59(4):167–172. [PubMed] [Google Scholar]
  11. Okamura M., Kanayama Y., Amastu K., Negoro N., Kohda S., Takeda T., Inoue T. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis. 1993 Jan;52(1):14–20. doi: 10.1136/ard.52.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Otterness I. G. Comparative activity of CP-17,193 and five established immunosuppressives toward the antigens SRBC and EL4. Clin Exp Immunol. 1981 Nov;46(2):332–339. [PMC free article] [PubMed] [Google Scholar]
  13. Takabayashi K., Koike T., Kurasawa K., Matsumura R., Sato T., Tomioka H., Ito I., Yoshiki T., Yoshida S. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol. 1989 Apr;51(1):110–117. doi: 10.1016/0090-1229(89)90211-0. [DOI] [PubMed] [Google Scholar]
  14. Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269–390. doi: 10.1016/s0065-2776(08)60342-9. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES